SEC Form 4 · accession 0001127602-15-012371
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & Co-CEO · Director
Period of report
Mar 19, 2015
Accepted (ET)
Mar 24, 2015 · 7:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 19, 2015 | M | 4,115 | $34.56 | A | 4,355 | D | |
| Common StockF3 | Mar 19, 2015 | S | 4,115 | $173.1902 | D | 240 | D | |
| Common StockF2 | Mar 19, 2015 | M | 5,547 | $30.75 | A | 5,787 | D | |
| Common StockF4 | Mar 19, 2015 | S | 1,204 | $173.4923 | D | 4,583 | D | |
| Common StockF5 | Mar 19, 2015 | S | 1,750 | $174.4177 | D | 2,833 | D | |
| Common StockF6 | Mar 19, 2015 | S | 1,734 | $175.4321 | D | 1,099 | D | |
| Common StockF7 | Mar 19, 2015 | S | 859 | $176.1218 | D | 240 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 533,094 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $34.56 | Mar 19, 2015 | M | 4,115 | D | Dec 30, 2005 | Dec 30, 2015 | Common Stock | 4,115 | 144,040 | D |
| Stock OptionsF2 | $30.75 | Mar 19, 2015 | M | 5,547 | D | Dec 26, 2009 | Dec 31, 2017 | Common Stock | 5,547 | 515,836 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- F3This transaction was executed in multiple trades at prices ranging from $172.92 to $173.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $173.00 to $173.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $174.07 to $174.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $175.00 to $175.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $176.01 to $176.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.